A Proof of Concept Study to Evaluate Administration of CN-105 in Patients With Acute Supratentorial Intracerebral Hemorrhage
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs CN 105 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions; Proof of concept
- Acronyms CATCH
- Sponsors AegisCN
- 08 Jul 2019 Status changed from recruiting to completed.
- 13 Dec 2018 Planned number of patients changed from 60 to 45.
- 13 Dec 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.